Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Pheochromocytoma × belzutifan × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1 CNS 1

Conditions

von Hippel-Lindau Disease 2 Pheochromocytoma 1 Paraganglioma 1 Kidney Neoplasms 1 Carcinoma, Renal Cell 1 Adenoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 1 copper dotatate CU-64 1 belzutifan 1 Lutetium-177 1 Lutetium 1 3-Iodobenzylguanidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04924075 2026-02-24

MK-6482-015

Merck Sharp & Dohme LLC

Phase 2 Recruiting

322 enrolled 1 FDA

von Hippel-Lindau Disease, Adenoma, Islet Cell, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡